UK Markets closed

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

·9-min read

Lille, France; Cambridge, MA; July 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2021:

  • 105,050 shares

  • €646 510.51

During the first half of 2021, total trading was:

  • On the buy side: 1,013,138 shares for a total amount of €4,450,737.46

  • On the sell side: 997,017 shares for a total amount of €4,409,259.22

During this same period, the number of trades were:

  • On the buy side: 1,926

  • On the sell side: 1,901

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares

  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4®, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. In January 2019, GENFIT signed a licensing agreement with Labcorp® to make NIS4® technology available for use in clinical research through their drug development subsidiary, Covance. In September 2020, GENFIT signed another licensing agreement with Labcorp® to commercialize NIS4® in the US and Canada as a Laboratory Developed Test. Since April 2021, Labcorp® has commercialized NASHnext™, powered by NIS4®, for use in the clinic. GENFIT also continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic (IVD) test supported by NIS4® technology. For more information, please visit: https://nis4.com. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

CONTACT

GENFIT | Investors

Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie BOYER – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

APPENDIX

H1 2021

Buy Side

Sell Side

Date

Number of executions

Number of shares

Traded amount in EUR

Number of executions

Number of shares

Traded amount in EUR

TOTAL

1 926

1 013 138

4 450 737,46

1 901

997 017

4 409 259,22

04/01/2021

42

25672

106 920,21

71

32091

134 234,09

05/01/2021

14

8728

36 139,94

18

9738

40 492,26

06/01/2021

26

16345

68 348,42

48

24876

104 598,85

07/01/2021

59

38324

167 542,18

100

56720

248 081,94

08/01/2021

39

20950

93 524,57

40

19303

86 857,90

11/01/2021

29

12249

55 019,69

39

13105

59 047,46

12/01/2021

30

16023

72 645,24

27

18099

82 659,40

13/01/2021

32

14570

65 700,79

17

12174

55 117,18

14/01/2021

28

17348

78 153,43

30

14764

67 203,51

15/01/2021

60

35785

161 995,83

60

34081

155 051,51

18/01/2021

40

23966

110 613,87

73

39800

184 482,55

19/01/2021

56

23753

117 337,68

74

24318

120 680,26

20/01/2021

42

21062

100 611,18

37

15576

75 030,60

21/01/2021

41

20032

93 587,50

28

15806

74 357,27

22/01/2021

52

33987

149 767,45

41

22203

97 905,68

25/01/2021

37

24138

101 879,11

21

14196

60 143,34

26/01/2021

79

40817

183 223,84

73

43569

196 046,12

27/01/2021

4

1295

5 490,92

15

6036

26 485,97

28/01/2021

4

1083

4 570,30

1

1

4,26

29/01/2021

16

10926

46 089,36

12

7687

32 565,82

01/02/2021

12

7005

29 622,62

24

11847

50 360,05

02/02/2021

9

7357

31 743,98

14

8628

37 392,54

03/02/2021

17

7020

30 384,81

11

5929

25 883,29

04/02/2021

16

10207

43 452,02

14

7846

33 541,57

05/02/2021

12

5629

23 702,93

8

5629

23 821,65

08/02/2021

13

7441

31 508,77

11

7442

31 661,91

09/02/2021

12

8636

36 438,91

16

6096

25 852,40

10/02/2021

188

107001

577 416,99

183

112206

615 056,07

11/02/2021

35

19001

91 212,97

24

11001

52 685,00

12/02/2021

27

16001

73 964,46

47

18001

83 440,58

15/02/2021

3

2000

9 320,00

13

3000

13 959,99

16/02/2021

13

9697

44 808,87

2

3987

18 580,18

17/02/2021

12

9223

42 301,11

11

10946

50 456,13

18/02/2021

18

27927

129 069,94

21

14571

67 510,65

19/02/2021

24

18850

85 089,84

20

18850

85 429,33

22/02/2021

20

10664

47 914,31

10

10310

46 520,47

23/02/2021

58

49098

217 409,38

54

45491

203 152,33

24/02/2021

16

8916

39 163,44

12

10015

44 235,35

25/02/2021

14

8939

39 050,74

12

8088

35 426,98

26/02/2021

13

7916

33 637,85

22

10021

42 678,94

01/03/2021

13

7778

33 253,13

12

9037

38 819,43

02/03/2021

18

7837

33 470,42

11

7659

32 893,64

03/03/2021

17

8704

37 345,30

23

8704

37 525,56

04/03/2021

15

5342

22 558,95

3

1790

7 569,95

05/03/2021

14

6415

26 520,31

7

3761

15 645,44

08/03/2021

16

6358

26 870,75

22

12983

54 845,52

09/03/2021

8

1848

7 809,44

4

1598

6 797,40

10/03/2021

5

2101

8 866,26

3

1053

4 464,83

11/03/2021

9

2860

11 942,04

4

1051

4 496,18

12/03/2021

16

6313

26 022,56

14

5432

22 504,99

15/03/2021

24

5436

22 450,14

14

5383

22 333,04

16/03/2021

1

1

4,12

1

1

4,12

17/03/2021

1

1

4,15

1

1

4,15

18/03/2021

3

1809

7 506,75

3

1809

7 542,93

19/03/2021

4

1731

7 098,71

5

931

3 835,70

22/03/2021

1

1

4,13

2

801

3 316,13

23/03/2021

13

2743

11 190,14

2

997

4 069,77

24/03/2021

1

1

4,05

1

1

4,05

25/03/2021

6

2053

8 270,90

3

1163

4 698,55

26/03/2021

3

2053

8 270,90

16

891

3 617,46

29/03/2021

5

1501

6 052,02

3

2053

8 311,90

30/03/2021

1

1

4,05

1

1

4,05

31/03/2021

3

1056

4 224,01

1

1

4,01

01/04/2021

9

4221

16 884,04

11

4221

16 987,41

06/04/2021

13

5226

20 659,74

7

2501

9 923,12

07/04/2021

1

1

3,93

1

1

3,93

08/04/2021

4

2229

8 849,40

6

3964

15 821,83

09/04/2021

12

4465

17 737,97

8

1727

6 908,02

12/04/2021

3

1385

5 474,59

6

1007

4 007,86

13/04/2021

19

6298

24 858,65

16

6203

24 675,97

14/04/2021

3

826

3 237,92

5

826

3 254,42

15/04/2021

32

10745

41 274,77

14

4684

18 053,68

16/04/2021

39

7683

28 610,41

9

3861

14 409,25

19/04/2021

12

5890

21 906,44

16

6911

25 851,15

20/04/2021

24

4969

18 183,81

5

1647

6 031,91

21/04/2021

6

2870

10 381,19

6

4140

15 132,90

22/04/2021

11

5833

21 566,18

17

7975

29 638,37

23/04/2021

14

6721

24 441,05

13

4659

16 934,21

26/04/2021

5

3135

11 225,09

2

1134

4 066,55

27/04/2021

5

2940

10 842,46

15

4941

18 139,45

28/04/2021

23

2063

7 588,89

7

2940

10 901,34

29/04/2021

31

11399

43 054,36

28

12153

46 058,05

30/04/2021

3

1099

4 097,06

5

2107

7 866,76

03/05/2021

25

12705

49 089,32

28

18531

72 131,18

04/05/2021

14

6739

25 453,74

10

2653

10 086,18

05/05/2021

1

1

3,72

1

1

3,72

06/05/2021

3

1055

3 861,36

1

1

3,73

07/05/2021

5

1905

6 921,32

2

1055

3 882,40

10/05/2021

6

2867

10 286,62

4

1859

6 713,11

11/05/2021

18

3993

14 131,39

2

796

2 811,50

12/05/2021

12

5025

17 910,96

17

7214

25 864,86

13/05/2021

14

7985

27 704,60

7

4952

17 150,16

14/05/2021

7

4019

13 869,77

5

2031

7 014,57

17/05/2021

10

3964

13 587,60

5

3089

10 727,42

18/05/2021

4

2001

6 819,43

1

1

3,42

19/05/2021

9

3015

10 175,08

8

7048

23 806,73

20/05/2021

15

22232

71 627,06

18

22501

73 568,37

21/05/2021

14

1001

3 273,30

1

1

3,3

24/05/2021

18

7349

23 686,34

4

1621

5 185,21

25/05/2021

14

4677

15 205,07

30

9976

32 662,72

26/05/2021

7

3081

10 127,31

7

2226

7 389,65

27/05/2021

5

2226

7 389,65

01/06/2021

1

1

3,34

1

1

3,34

02/06/2021

6

1842

6 207,03

03/06/2021

30

8641

29 981,11

09/06/2021

1

1

3,50

1

1

3,50

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting